Live Attenuated Vaccines Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Size, Share & Trends, Drivers, Restraints, Opportunities, Manufacturer, Applications, And Segments

  • AMR-1066366
  • May 2021
  • Pharmaceuticals
  • 148 Pages
The Live Attenuated Vaccines market research report provides an in-depth analysis of the currents trends, latest developments, scenario, market size, various drivers, restraints, and major players along with their profile details. Research report offers the historic data for year 2018 and 2019 and also provides the forecast data from year 2020 to 2028 which is based on revenue (USD Million). With the help of all these information research report helps the market participants to improve market positions. With the help of all these insights Live Attenuated Vaccines market research report recommends a business strategy for present market participants to strengthen their position in the market.
 
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2020
Forecast Period Covered 2020 – 2028
Units for value Revenue in USD million and CAGR from 2020 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Companies Covered Emergent BioSolutions Inc., GlaxoSmithKline plc, BioDiem, AstraZeneca, Merck & Co., Inc., Pfizer Inc., Sanofi, Serum institute of India Pvt. Ltd., CSL Limited, Vivaldi Biosciences Inc.
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa

COVID-19 Impact Analysis
The analysis of covid-19 is based on the impact of the current pandemic situation on market scenarios. This includes impact of covid-19 outbreak on overall revenue, market segments as well as regional market. The report also puts light on detailed impact analysis by taking into consideration all the government policies imposed during the pandemic situation, temporary shutdown of manufacturing units, current state of supply chain and distributors, and its future impacts on the growth of overall market. The market study will assist user to understand the global demand and impose strategic business plans to compete with the peers.

Furthermore, the research report includes the detailed information about major players and provides the data regarding the current market scenario as well as upcoming market opportunities or challenges. Similarly, in segment report covers the types, and applications according to the countries and key regions. The research report consists the various drivers and restraints for Live Attenuated Vaccines market along with their effects over the forecast period. Similarly, according to the region Live Attenuated Vaccines market research report includes the study of opportunities available in the market situation.

The Live Attenuated Vaccines market research report provides the in-depth data analysis by using the various graphs, figures, charts, and tables. Furthermore, the report provides the different business challenges which are impacting market growth in all direction.

Major Key Players for Global Live Attenuated Vaccines Market:
The Live Attenuated Vaccines market research report offers the company profile of major key players including progress trends, competitive landscape breakdown, and key in regions development status. Emergent BioSolutions Inc., GlaxoSmithKline plc, BioDiem, AstraZeneca, Merck & Co., Inc., Pfizer Inc., Sanofi, Serum institute of India Pvt. Ltd., CSL Limited, Vivaldi Biosciences Inc.

Live Attenuated Vaccines Market Segmentation Analysis:
by Type
Viral and Bacterial
End User
Hospitals
Clinics
Research Institutes
Other End Users

Global Live Attenuated Vaccines Market Segmentation by Regions:
In regional analysis, Live Attenuated Vaccines market research report provides the detailed analysis from various regions and also contains the detailed analysis of country. Along with market revenue, market value report also offers the forecast analysis for the following countries and regions. Global Live Attenuated Vaccines market report covers the various geographical regions such as North America, Asia-Pacific, Europe, Latin America, and Middle East & Africa. Also, various countries included are Canada, U.K., France, the U.S., Japan, China, India, and Germany and so on.

North America Region for Live Attenuated Vaccines Market: Value and Forecast
  • U.S.
  • Canada
 Europe Region for Live Attenuated Vaccines Market: Value and Forecast
  • UK
  • Germany
  • France
  • Rest of the Europe
 Asia Pacific Region for Live Attenuated Vaccines Market: Value and Forecast
  • China
  • Japan
  • India
  • Rest of the Asia Pacific
 Latin America Region for Live Attenuated Vaccines Market: Value and Forecast
  • Mexico
  • Brazil
  • Rest of the Latin America
 Middle East and Africa for Live Attenuated Vaccines Market: Value and Forecast
  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa


Important Points Covered by Report:
  • To analyze the value of the Live Attenuated Vaccines market, according to the key region.
  • To study the Live Attenuated Vaccines market current trends, prospects and also their participation in the entire sector.
  • Report consists the in-depth information related to the region/countries, major key players, current trends and their analysis, product type, applications, and other background information
  • Report provides the detailed information about drivers, restraints and future scope of Live Attenuated Vaccines market.
  • Report covers the information about historic data analysis as well as forecast period analysis.

Global Live Attenuated Vaccines research report consist the information about overall sales and revenue during the historic and forecasted period of 2018 to 2028. Additionally, this report covers the inside and out factual examination and the market elements and requests which give an entire situation of the business.

Key Analytical Areas:
The report aims to offer a complete solution to various businesses operating in the Live Attenuated Vaccines market in making strategic decisions based on credible information and actionable insights. Thereby, the report covers various aspects of your requirements such as industry overview, market dynamics, regional analysis and competitive landscape. The report aims to provide insights to businesses in the Live Attenuated Vaccines market for numerous purposes such as:

    1. Strategic Decision Making:
With the help of this report, key decision makers can quickly analyze and identify growth opportunities in terms of numerous segments across various geographical regions. Thereby, this report enables organizations to identify and make strategic investments in specific market segments in order to gain maximum return on investment.

     2. Actionable Insights:
The report offers a deep dive into how companies are leveraging market conditions to make the most in the Live Attenuated Vaccines market. Thereby, the report offers numerous actionable insights into the best practices and key success factors relevant in the Live Attenuated Vaccines market. Using the insights included in the report, businesses can make quick decisions to achieve success in business operations.

     3. Competitive Snapshot:
In addition, to detailed information on the companies operating in the Live Attenuated Vaccines market, the report also includes a competitive snapshot of all the companies covered in the report. Thereby, this offers a visual representation of how all the companies stand comparatively based on their competencies, geographic presence, market hold, years of operations, employee and financial strength, among others.

Manufacturers and Segments

  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc
  • BioDiem
  • AstraZeneca
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi
  • Serum institute of India Pvt. Ltd.
  • CSL Limited
  • Vivaldi Biosciences Inc.
  • Viral and Bacterial
  • End UserEnd Users

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summarysegment Form
     2.1. Global Live Attenuated Vaccines Market Snapshot
          2.1.1. Global Live Attenuated Vaccines Market By Type,2019
               2.1.1.1.Viral and Bacterial
          2.1.2. Global Live Attenuated Vaccines Market By End UserEnd Users,2019
               2.1.2.1.End UserEnd Users
          2.1.3. Global Live Attenuated Vaccines Market By End-use,2019
          2.1.4. Global Live Attenuated Vaccines Market By Geography,2019

3. Global Live Attenuated Vaccines Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Live Attenuated Vaccines Market Size (US$), By Type, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Type, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Type, 2020
     4.2. Global Live Attenuated Vaccines Market Size (US$), By Type, 2018 – 2028

5. Global Live Attenuated Vaccines Market Size (US$), By End UserEnd Users, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By End UserEnd Users, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By End UserEnd Users, 2020
     5.2. Global Live Attenuated Vaccines Market Size (US$), By End UserEnd Users, 2018 – 2028

6. Global Live Attenuated Vaccines Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Live Attenuated Vaccines Market Size (US$), By End-use, 2018 – 2028

7. Global Live Attenuated Vaccines Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Live Attenuated Vaccines Market Analysis, 2018 – 2028 
          7.2.1. North America Live Attenuated Vaccines Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Live Attenuated Vaccines Market Size (US$), By Type, 2018 – 2028
          7.2.3. North America Live Attenuated Vaccines Market Size (US$), By End UserEnd Users, 2018 – 2028
          7.2.4. North America Live Attenuated Vaccines Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Live Attenuated Vaccines Market Analysis, 2018 – 2028 
          7.3.1.  Europe Live Attenuated Vaccines Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Live Attenuated Vaccines Market Size (US$), By Type, 2018 – 2028
          7.3.3. Europe Live Attenuated Vaccines Market Size (US$), By End UserEnd Users, 2018 – 2028
          7.3.4. Europe Live Attenuated Vaccines Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Live Attenuated Vaccines Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Live Attenuated Vaccines Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Live Attenuated Vaccines Market Size (US$), By Type, 2018 – 2028
          7.4.3. Asia Pacific Live Attenuated Vaccines Market Size (US$), By End UserEnd Users, 2018 – 2028
          7.4.4. Asia Pacific Live Attenuated Vaccines Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Live Attenuated Vaccines Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Live Attenuated Vaccines Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Live Attenuated Vaccines Market Size (US$), By Type, 2018 – 2028
          7.5.3. Latin America Live Attenuated Vaccines Market Size (US$), By End UserEnd Users, 2018 – 2028
          7.5.4. Latin America Live Attenuated Vaccines Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Live Attenuated Vaccines Market Analysis, 2018 – 2028 
          7.6.1.  MEA Live Attenuated Vaccines Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Live Attenuated Vaccines Market Size (US$), By Type, 2018 – 2028
          7.6.3. MEA Live Attenuated Vaccines Market Size (US$), By End UserEnd Users, 2018 – 2028
          7.6.4. MEA Live Attenuated Vaccines Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Live Attenuated Vaccines Providers
        8.4.1 Emergent BioSolutions Inc.
                8.4.1.1 Business Description
                8.4.1.2 Emergent BioSolutions Inc. Geographic Operations
                8.4.1.3 Emergent BioSolutions Inc. Financial Information
                8.4.1.4 Emergent BioSolutions Inc. Product Positions/Portfolio
                8.4.1.5 Emergent BioSolutions Inc. Key Developments
        8.4.2 GlaxoSmithKline plc
                8.4.2.1 Business Description
                8.4.2.2 GlaxoSmithKline plc Geographic Operations
                8.4.2.3 GlaxoSmithKline plc Financial Information
                8.4.2.4 GlaxoSmithKline plc Product Positions/Portfolio
                8.4.2.5 GlaxoSmithKline plc Key Developments
        8.4.3 BioDiem
                8.4.3.1 Business Description
                8.4.3.2 BioDiem Geographic Operations
                8.4.3.3 BioDiem Financial Information
                8.4.3.4 BioDiem Product Positions/Portfolio
                8.4.3.5 BioDiem Key Developments
        8.4.4 AstraZeneca
                8.4.4.1 Business Description
                8.4.4.2 AstraZeneca Geographic Operations
                8.4.4.3 AstraZeneca Financial Information
                8.4.4.4 AstraZeneca Product Positions/Portfolio
                8.4.4.5 AstraZeneca Key Developments
        8.4.5 Merck & Co., Inc.
                8.4.5.1 Business Description
                8.4.5.2 Merck & Co., Inc. Geographic Operations
                8.4.5.3 Merck & Co., Inc. Financial Information
                8.4.5.4 Merck & Co., Inc. Product Positions/Portfolio
                8.4.5.5 Merck & Co., Inc. Key Developments
        8.4.6 Pfizer Inc.
                8.4.6.1 Business Description
                8.4.6.2 Pfizer Inc. Geographic Operations
                8.4.6.3 Pfizer Inc. Financial Information
                8.4.6.4 Pfizer Inc. Product Positions/Portfolio
                8.4.6.5 Pfizer Inc. Key Developments
        8.4.7 Sanofi
                8.4.7.1 Business Description
                8.4.7.2 Sanofi Geographic Operations
                8.4.7.3 Sanofi Financial Information
                8.4.7.4 Sanofi Product Positions/Portfolio
                8.4.7.5 Sanofi Key Developments
        8.4.8 Serum institute of India Pvt. Ltd.
                8.4.8.1 Business Description
                8.4.8.2 Serum institute of India Pvt. Ltd. Geographic Operations
                8.4.8.3 Serum institute of India Pvt. Ltd. Financial Information
                8.4.8.4 Serum institute of India Pvt. Ltd. Product Positions/Portfolio
                8.4.8.5 Serum institute of India Pvt. Ltd. Key Developments
        8.4.9 CSL Limited
                8.4.9.1 Business Description
                8.4.9.2 CSL Limited Geographic Operations
                8.4.9.3 CSL Limited Financial Information
                8.4.9.4 CSL Limited Product Positions/Portfolio
                8.4.9.5 CSL Limited Key Developments
        8.4.10 Vivaldi Biosciences Inc.
                8.4.10.1 Business Description
                8.4.10.2 Vivaldi Biosciences Inc. Geographic Operations
                8.4.10.3 Vivaldi Biosciences Inc. Financial Information
                8.4.10.4 Vivaldi Biosciences Inc. Product Positions/Portfolio
                8.4.10.5 Vivaldi Biosciences Inc. Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Live Attenuated Vaccines Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Live Attenuated Vaccines Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Live Attenuated Vaccines Market Revenue, By End UserEnd Users, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Live Attenuated Vaccines Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Live Attenuated Vaccines Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Live Attenuated Vaccines Market Revenue, By End UserEnd Users, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Live Attenuated Vaccines Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Live Attenuated Vaccines Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Live Attenuated Vaccines Market Revenue, By End UserEnd Users, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Live Attenuated Vaccines Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Live Attenuated Vaccines Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Live Attenuated Vaccines Market Revenue, By End UserEnd Users, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Live Attenuated Vaccines Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Live Attenuated Vaccines Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Live Attenuated Vaccines Market Revenue, By End UserEnd Users, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Live Attenuated Vaccines Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Live Attenuated Vaccines: Market Segmentation 
FIG. 2 Global Live Attenuated Vaccines Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Live Attenuated Vaccines Market, By Type, 2019 (US$ Mn) 
FIG. 5 Global Live Attenuated Vaccines Market, By End UserEnd Users, 2019 (US$ Mn) 
FIG. 6 Global Live Attenuated Vaccines Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Live Attenuated Vaccines Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Live Attenuated Vaccines Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Live Attenuated Vaccines Providers, 2019
FIG. 11 Global Live Attenuated Vaccines Market Revenue Contribution, By Type, 2019 & 2028 (Value %) 
FIG. 12 Global Live Attenuated Vaccines Market Revenue Contribution, By End UserEnd Users, 2019 & 2028 (Value %) 
FIG. 13 Global Live Attenuated Vaccines Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Live Attenuated Vaccines Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Live Attenuated Vaccines Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Live Attenuated Vaccines Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Live Attenuated Vaccines Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Live Attenuated Vaccines Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Live Attenuated Vaccines market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Live Attenuated Vaccines Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Live Attenuated Vaccines Market Value, By Segment1, 2018 – 2028
TABLE  North America Live Attenuated Vaccines Market Value, By Segment2, 2018 – 2028
TABLE  North America Live Attenuated Vaccines Market Value, By Country, 2018 – 2028
TABLE  Europe Live Attenuated Vaccines Market Value, By Segment1, 2018 – 2028
TABLE  Europe Live Attenuated Vaccines Market Value, By Segment2, 2018 – 2028
TABLE  Europe Live Attenuated Vaccines Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Live Attenuated Vaccines Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Live Attenuated Vaccines Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Live Attenuated Vaccines Market Value, By Country, 2018 – 2028
TABLE  Latin America Live Attenuated Vaccines Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Live Attenuated Vaccines Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Live Attenuated Vaccines Market Value, By Country, 2018 – 2028
TABLE  MEA Live Attenuated Vaccines Market Value, By Segment1, 2018 – 2028
TABLE  MEA Live Attenuated Vaccines Market Value, By Segment2, 2018 – 2028
TABLE  MEA Live Attenuated Vaccines Market Value, By Country, 2018 – 2028
TABLE  Emergent BioSolutions Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  GlaxoSmithKline plc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  BioDiem: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  AstraZeneca: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Merck & Co., Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Pfizer Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Sanofi: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Serum institute of India Pvt. Ltd.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  CSL Limited: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Vivaldi Biosciences Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global Live Attenuated Vaccines Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Live Attenuated Vaccines Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Live Attenuated Vaccines Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Live Attenuated Vaccines Market, By Geography, 2019 (US$ Mn)
FIG.  Global Live Attenuated Vaccines Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Live Attenuated Vaccines Providers, 2016
FIG.  Global Live Attenuated Vaccines Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Live Attenuated Vaccines Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. Live Attenuated Vaccines Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Live Attenuated Vaccines Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Live Attenuated Vaccines Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Live Attenuated Vaccines Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Live Attenuated Vaccines Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Live Attenuated Vaccines Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Live Attenuated Vaccines Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Live Attenuated Vaccines Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Live Attenuated Vaccines Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Live Attenuated Vaccines Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Live Attenuated Vaccines Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Live Attenuated Vaccines Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Live Attenuated Vaccines Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Live Attenuated Vaccines Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Live Attenuated Vaccines Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Live Attenuated Vaccines Market Value, 2018 – 2028, (US$ Mn)